Table 1 Baseline characteristics of study patients
Characteristic | Total (n = 297) | Nevirapine plasma conc. ≥3.0 mg/L (n = 282) | Nevirapine plasma conc. <3.0 mg/L (n = 15) |
|---|---|---|---|
Sex, female | 201 (67.7) | 192 (68.1) | 9 (60.0) |
Age (years) | 39.1 (32.8-45.2) | 39.2 (33.1-45.2) | 33.3 (30.9-42.8) |
Time on ART (months) | 28.5 (25.8-33.5) | 28.1 (25.9-32.6) | 31.1 (24.4-41.2) |
NRTI backbone | Â | Â | Â |
  zidovudine | 235 (79.1) | 223 (79.1) | 12 (80.0) |
  tenofovir | 19 (6.4) | 17 (6.0) | 2 (13.3) |
HIV-RNA >400 copies/mL* | 21 (8.9) | 18 (8.1) | 3 (23.1) |
30-day adherence | Â | Â | Â |
  100% | 260 (91.6) | 248 (91.9) | 12 (85.7) |
  95- < 100% | 19 (6.7) | 18 (6.7) | 1 (7.1) |
  <95% | 5 (1.8) | 4 (1.5) | 1 (7.1) |
3-day adherence (any pills missed) | 9 (3.3) | 6 (2.3) | 3 (20.0) |
CD4 cell count (cells/mm3) | 363 (265–509) | 385 (269.5-511) | 299 (211–354) |